This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Jan. 4, 2013 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in
China, announced today that it has closed the acquisition of 19.98% of indirect ownership of The
University of Texas MD Anderson Cancer Center Proton Therapy Center (MD Anderson Proton Therapy Center).
The company announced the signing of a definite agreement in connection with the acquisition on
December 11, 2012. MD Anderson Proton Therapy Center is a leading proton treatment center in the world. Concord Medical plans to invest and operate two proton centers in
China. The transaction will enable Concord Medical to expand its expertise and knowledge base in preparation for the operation of future proton centers.
After the closing, Concord Medical becomes the second largest owner of the MD Anderson Proton Therapy Center, behind MD Anderson Cancer Center. Concord Medical will join both the Board of Directors of the PTC-Houston Management, LP, the general partner of the center, and the center's Advisory Committee.
"The acquisition of interest in MD Anderson Proton Therapy Center plays a key role in accelerating Concord Medical's strategic plan to build and operate proton centers in
China," says Dr.
Jianyu Yang, CCM Chairman and CEO. "The transaction solidifies CCM's position as a leading radiotherapy operator in China. We look forward to working closely with MD Anderson Proton Therapy Center in multiple areas."
Under the terms of the agreement, CCM paid an undisclosed amount in cash to purchase a minority interest in the general partner and facility manager of the MD Anderson Proton Therapy Center. CCM will be entitled to receive both management fees and cash distribution. The net impact to CCM is expected to be accretive to EPS in 2013.